Treatment patterns of knee osteoarthritis patients in Korea
2
조회
0
다운로드
13
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the treatment patterns of knee osteoarthritis (OA) patients in South Korea. Methods: Using the Korean nationwide claims database, all knee OA patients in Korea during 2014 were identified by the knee OA diagnostic code (M17) or any OA diagnostic code (M15 to M19) in combination with a procedure for a knee X-ray. Patterns of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CSs), analgesics, and symptomatic slow acting drugs for OA (SYSADOA) were analyzed. Prevalence and characteristics of knee OA patients who received a CS intra-articular injection (IAI) were also evaluated. Results: We identified 2,016,516 knee OA patients whose age (mean ± standard deviation) was 63.2 ± 10.8 years. The number of patients with at least one use of NSAIDs, analgesics, CS, and SYSADOA were 82.5%, 32.2%, 8.6%, and 43.4%, respectively. The use of herbal SYSADOAs was 29.7%. For regular users (medication possession ratios ≥ 50%), the use of NSAIDs was substantially decreased (48.8%), while the use of SYSADOA (37.3%) and CS (6.7%) were not significantly changed. The number of CS IAI users among knee OA patients was 0.18%; they were slightly older (64.4 ± 10.9 vs. 63.2 ± 10.8, p < 0.01) and more skewed towards females (75.7% vs. 71.5%, p < 0.01) than patients who had not received CS IAI. Conclusions: In Korea, the use of SYSADOA or CS in knee OA patients was relatively high. Further studies on the effectiveness and the safety of these treatment options for knee OA are needed.
Abstract
Background/Aims: To evaluate the treatment patterns of knee osteoarthritis (OA) patients in South Korea. Methods: Using the Korean nationwide claims database, all knee OA patients in Korea during 2014 were identified by the knee OA diagnostic code (M17) or any OA diagnostic code (M15 to M19) in combination with a procedure for a knee X-ray. Patterns of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CSs), analgesics, and symptomatic slow acting drugs for OA (SYSADOA) were analyzed. Prevalence and characteristics of knee OA patients who received a CS intra-articular injection (IAI) were also evaluated. Results: We identified 2,016,516 knee OA patients whose age (mean ± standard deviation) was 63.2 ± 10.8 years. The number of patients with at least one use of NSAIDs, analgesics, CS, and SYSADOA were 82.5%, 32.2%, 8.6%, and 43.4%, respectively. The use of herbal SYSADOAs was 29.7%. For regular users (medication possession ratios ≥ 50%), the use of NSAIDs was substantially decreased (48.8%), while the use of SYSADOA (37.3%) and CS (6.7%) were not significantly changed. The number of CS IAI users among knee OA patients was 0.18%; they were slightly older (64.4 ± 10.9 vs. 63.2 ± 10.8, p < 0.01) and more skewed towards females (75.7% vs. 71.5%, p < 0.01) than patients who had not received CS IAI. Conclusions: In Korea, the use of SYSADOA or CS in knee OA patients was relatively high. Further studies on the effectiveness and the safety of these treatment options for knee OA are needed.
참고문헌 (24)
- Murray CJ, "Disability-adjusted life years(DALYs)for 291 diseases and injuries in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2197~2223 (2012)
- Nguyen US, "Increasing prevalence of knee pain and symptomatic knee osteoarthritis : survey and cohort data", Ann Intern Med, 155, pp.725~732 (2011)
- Peat G, "Knee pain and osteoarthritis in older adults : a review of community burden and current use of primary health care", Ann Rheum Dis, 60, pp.91~97 (2001)
- 김인제, "The Prevalence of Knee Osteoarthritis in Elderly Community Residents in Korea", Journal of Korean Medical Science, 25(2), pp.293~298 (2010), 대한의학회
- Park JH, "Prevalence of symptomatic hip, knee, and spine osteoarthritis nationwide health survey analysis of an elderly Korean population", Medicine (Baltimore), 96, pp.e6372~ (2017)
- Jevsevar DS, "Treatment of osteoarthritis of the knee : evidence-based guideline, 2nd edition", J Am Acad Orthop Surg, 21, pp.571~576 (2013)
- Hochberg MC, "American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee", Arthritis Care Res(Hoboken), 64, pp.465~474 (2012)
- National Clinical Guideline Centre for Acute, "Osteoarthritis : Care and Management in Adults", National Clinical Guideline Centre, ~ (2014)
- McAlindon TE, "OARSI guidelines for the non-surgical management of knee osteoarthritis", Osteoarthritis Cartilage, 22, pp.363~388 (2014)
- Jordan KM, "EULAR Recommendations 2003 : an evidence based approach to the management of knee osteoarthritis : report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials(ESCISIT)", Ann Rheum Dis, 62, pp.1145~1155 (2003)
- Wilson N, "Drug utilization in patients with OA : a population-based study", Rheumatology(Oxford), 54, pp.860~867 (2015)
- Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- Park HR, "Identification of knee osteoarthritis patients in the claims database", The 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) (2017)
- Hartog A, "The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators", Phytomedicine, 15, pp.313~320 (2008)
- Yoo WH, "Efficacy and safety of PG201(Layla(R))and celecoxib in the treatment of symptomatic knee osteoarthritis : a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study", Rheumatol Int, 34, pp.1369~1378 (2014)
- Shin SS, "Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice", Rheumatology(Oxford), 42, pp.665~672 (2003)
- Lee SY, "SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease : first therapeutic application for the treatment of osteoarthritis", Arch Pharm Res, 34, pp.1773~1777 (2011)
- Lapane KL, "Factors associated with the use of hyaluronic acid and corticosteroid injections among patients with radiographically confirmed knee osteoarthritis : a retrospective data analysis", Clin Ther, 39, pp.347~358 (2017)
- 채민경, "지역약국 방문 성인의 일반의약품 복용실태 및 일반의약품과 처방의약품과의 상호작용 연구", 한국임상약학회지, 23(1), pp.49~56 (2013), 한국임상약학회
- Seo HJ, "Prevalence and factors affecting glucosamine use in Korea : a survey-based study", Rheumatol Int, 33, pp.1627~1631 (2013)
- Clegg DO, "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis", N Engl J Med, 354, pp.795~808 (2006)
- Hochberg MC, "Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis : a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib", Ann Rheum Dis, 75, pp.37~44 (2016)
- Runhaar J, "Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis : a systematic review and individual patient data meta-analysis from the OA trial bank", Ann Rheum Dis, 76, pp.1862~1869 (2017)
- da Costa BR, "Intra-articular corticosteroids for osteoarthritis of the knee", JAMA, 316, pp.2671~2672 (2016)